MORRISTOWN, N.J., Feb. 01, 2019 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc. announced the publication of a paper in Clinical Infectious Disease—a journal of the Infectious Disease Society of America entitled, Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia (CAP) Patients at High Risk for Severe Outcomes.  BioAegis, together with Investigators at Vanderbilt and Northwestern Universities as well as the CDC, retrospectively analyzed samples from the previously completed CDC-Sponsored EPIC study that prospectively followed several thousand CAP patients.

Read the full press release here: Publication in “Clinical Infectious Diseases”


New Patents Issued Across Multiple Geographies in US, China, Hong Kong and Australia

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December, 2017) BioAegis Therapeutics announces that during 2018 its patent portfolio expanded globally in multiple indications. The newly issued patents extend coverage in infection, inflammatory disease, and neurological disease in the United States, China, Honk Kong and Australia. The plasma gelsolin portfolio now includes 30 issued patents and many pending applications.


MORRISTOWN, NJ, (September 17, 2018) BioAegis Therapeutics Inc. announced that it has begun patient enrollment in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in Community-Acquired Pneumonia (CAP) in Australasia.* The clinical-stage company is focused on a novel approach to address infectious, inflammatory and degenerative diseases through a portfolio built around rhu-pGSN technology. Separately, the company announced that it has closed a $4.1 million equity round.

Read the full press release here: Bioaegis-Therapeutics-Enrolls-Patients-Final
 


MORRISTOWN, NJ (BIOAEGIS THERAPEUTICS) June 19, 2018.  BioAegis Therapeutics Inc., a clinical-stage company focused on developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around recombinant plasma gelsolin (rhu-pGSN) technology presented data at ASM-Microbe 2018 demonstrating that low admission plasma gelsolin concentrations can help identify community-acquired pneumonia (CAP) patients at high risk for severe adverse outcomes.

Read the full press release here: ASM Microbe Abstract Presentation

 


New Patents Issued Across Multiple Geographies in US, Europe and Japan

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December, 2017) BioAegis Therapeutics announces that during 2017 its patent portfolio expanded globally in multiple indications. The newly issued patents extend coverage in inflammatory disease, neurological disease and renal failure in the United States, Europe and Japan. The plasma gelsolin portfolio now includes 26 issued patents and many pending applications.